New diabetes pill enters early human testing

NCT ID NCT07234864

First seen Nov 19, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This early-stage study tests a new oral medication, ZE63-0302, in 60 adults with type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. Participants must have had diabetes for at least 7 years and be on stable diabetes medicines (excluding insulin). This is a first step to see if the drug is safe enough for larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emeritus Research Camberwell

    Melbourne, Victoria, 3124, Australia

  • Emeritus Research Sydney

    Botany, New South Wales, 2019, Australia

  • Momentum Clinical Research Sunshine

    Melbourne, Victoria, 3021, Australia

  • Momentum Clinical Research Taringa

    Brisbane, Queensland, 4068, Australia

  • Momentum Dunedin

    Dunedin, Otago, 9016, New Zealand

  • Momentum Wellington

    Wellington, Wellington Region, 6011, New Zealand

  • PCRN Christchurch

    Christchurch, Canterbury, 8013, New Zealand

  • PCRN Rotorua

    Rotorua, Bay of Plenty, 3010, New Zealand

  • PCRN Waikato

    Hamilton, Waikato Region, 3200, New Zealand

  • The Republican Specialized Scientific and Prectical Medical Center of Endocrinology named after Academician Yo. Kh. Turakulov

    Tashkent, Tashkent, 100125, Uzbekistan

Conditions

Explore the condition pages connected to this study.